Pay in 4 interest-free payments of $16.25 Learn more
Ships within 48 hours · Estimated delivery Sep 6 - Sep 11
thereby interfering with a key step in the autophagic process
and pancreatic and breast cancers)
Currently CI994 is in phase III clinical trials for lung cancer
giving growth delays in A431 xenografts exceeding 50 days following oral administration
ISX9 is also shown to induce cardiomyogenic differentiation of Notch-activated epicardium-derived cells in vitro
OG-L002 - LSD1 Inhibitor. CAS# 1357302-64-7 60281 thereby interfering with a keyOG L002, CAS No. 1357302 64 7, is a highly potent and specific inhibitor of Lysine Specific Demethylase 1 (LSD1). It inhibits LSD1 in biochemical assay with an IC50 ~20 nM, and has moderate inhibitory activity against monoamine oxidases MAO A and MAO B with IC50 ~1. 38 M and 0. 72M respectively. It potently repressed herpes simplex virus (HSV) IE gene expression, genome replication, and reactivation from latency. OG L002 suppressed primary lytic
US$ 2190.00
US$ 1202.50